Drug treatments for obesity: orlistat, sibutramine, and rimonabant

Lancet

Volumn 369, Issue 9555, 2007, Pages 71-77

  Padwal, Raj S ^a   Majumdar, Sumit R ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOSPORIN; CYTOCHROME P450 3A4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELANOCORTIN; MONOAMINE OXIDASE INHIBITOR; MONOAMINE REUPTAKE INHIBITOR; PLACEBO; RIMONABANT; SEROTONIN AGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TRIACYLGLYCEROL LIPASE INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ABNORMAL FECES; ANXIETY; APPETITE; BLOOD PRESSURE; BODY MASS; BREAST CANCER; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; LIFESTYLE MODIFICATION; LONG TERM CARE; MENTAL DISEASE; MOOD DISORDER; NAUSEA; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULSE RATE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; THERMOGENESIS; VALVULAR HEART DISEASE; VITAMIN DEFICIENCY; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33845874637     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60033-6     Document Type: Review

References (77)

1. Schwartz M., Woods S., Porte Jr. D., Seeley R., and Baskin D. Central nervous system control of food intake. Nature 404 (2000) 661-671
2. Leibel R., Rosenbaum M., and Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 332 (1995) 621-628
3. Rosenbaum M., Leibel R., and Hirsch J. Obesity. N Engl J Med 337 (1997) 396-407
4. Haslam D., and James W. Obesity. Lancet 366 (2005) 1197-1209
5. Gardner G., and Halweil B. Overfed and underfed: the global epidemic of malnutrition. Worldwatch Institute (March, 2000). http://www.worldwatch.org/node/840 (accessed Jan 20, 2006)
6. Hill J., Wyatt H., Phelan S., and Wing R. The National Weight Control Registry: is it useful in helping deal with our obesity epidemic?. J Nutr Educ Behav 37 (2005) 206-210
7. National Heart, Lung, and Blood Institute Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report (1998), US Department of Health and Human Services, Bethesda, MD
8. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335 (1996) 609-616
9. Connolly H., Crary J., McGoon M., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
10. Blanck H., Khan L., and Serdula M. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Prev Med 39 (2004) 1243-1248
11. Avenell A., Broom J., Brown T., et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 8 (2004) 1-182
12. Goldstein D. Beneficial effects of modest weight loss. Int J Obes Relat Metab Disord 16 (1992) 397-415
13. European Agency for the Evaluation of Medicinal Products. Note for guidance on clinical investigation of drugs used in weight control (1997). http://www.emea.eu.int/pdfs/human/ewp/028196en.pdf (accessed June 5, 2006)
14. Haddock C., Poston W., Dill P., Foreyt J., and Ericsson M. Pharmacotherapy for obesity. Int J Obes Relat Metab Disord 26 (2002) 262-273
15. Padwal R., Li S., and Lau D. Long-term pharmacotherapy for overweight and obesity. Int J Obes Relat Metab Disord 27 (2003) 1437-1446
16. Padwal R., Li S., and Lau D. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 4 (2003) CD004094
17. Arbeeny C. Addressing the unmet medical need for safe and effective weight loss therapies. Obes Res 12 (2004) 1191-1196
18. Bays H. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 12 (2004) 1197-1211
19. Correia M., and Haynes W. Emerging drugs for obesity. Expert Opin Emerg Drugs 10 (2005) 643-660
20. Halford J. Pharmacotherapy for obesity. Appetite 46 (2006) 6-10
21. Hauptman J., Jeunet F., and Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0467 (tetrahydrolipstatin). Am J Clin Nutr 55 (1992) 309S-313S
22. Weibel E., Hadvary P., Hochuli E., Kupfer E., and Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini, I: producing organism, fermentation, isolation and biological activity. J Antibiot (Tokyo) 40 (1987) 1081-1085
23. European Medicines Agency. Xenical scientific discussion (2005). http://www.emea.eu.int/humandocs/PDFs/EPAR/Xenical/106698en6.pdf (accessed July 4, 2006)
24. McNeely W., and Benfield P. Orlistat. Drugs 56 (1998) 241-249
25. Torgerson J., Hauptman J., Boldrin M., and Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care 27 (2004) 155-161
26. Zhi J., Moore R., Kanitra L., and Mulligan T. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine and simvastatin) in healthy subjects. J Clin Pharmacol 43 (2003) 428-435
27. Zhi J., Moore R., Kanitra L., and Mulligan T. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in health subjects. J Clin Pharmacol 42 (2002) 1011-1019
28. MacWalter R., Fraser H., and Armstrong K. Orlistat enhances warfarin effect. Ann Pharmacother 37 (2003) 510-512
29. McNeely W., and Goa K. Sibutramine: a review of its contribution to the management of obesity. Drugs 56 (1998) 1093-1124
30. Lean M. How does sibutramine work?. Int J Obes Relat Metab Disord 25 suppl 4 (2001) S8-S11
31. Luscombe G., Hopcroft R., Thomas P., and Buckett W. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 28 (1989) 129-134
32. McNulty S., Ur E., and Williams G. A randomized trial of sibutramine in the management of type 2 diabetic patients treated with metformin. Diabetes Care 26 (2003) 125-131
33. Sanchez-Reyes L., Fanghanel G., Yamamoto J., Martinez-Rivas L., Campos-Franco E., and Berber A. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus. Clin Ther 26 (2004) 1427-1435
34. Wadden T., Berkowitz R., Womble L., et al. Randomised trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 (2005) 2111-2120
35. Medical News Today. Data demonstrate impact of weight loss with sibutramine on cardiovascular risk factors for obese patients (May, 2004). http://www.medicalnewstoday.com/index.php?newsid=8859 (accessed Jan 27, 2006)
36. Bach D., Rissanen A., Mendel C., et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res 7 (1999) 363-369
37. Zannad F., Gille B., Grentzinger A., et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 144 (2002) 508-515
38. Nisoli E., and Carruba M. A benefit-risk assessment of sibutramine in the management of obesity. Drug Safety 26 (2003) 1027-1048
39. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 166 (2002) 1307-1308
40. European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products opinion following an article 31 referral: sibutramine (2002). http://www.emea.eu.int/pdfs/human/referral/451402en.pdf (accessed June 5, 2006)
41. Mechoulam R. Cannabinoids as therapeutic agents (1986), CRC Press, Boca Raton
42. Lambert D., and Fowler C. The endocannabinoid system: drug targets, lead compounds and potential therapeutic applications. J Med Chem 48 (2005) 5059-5087
43. Di Marzo D., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
44. De Petrocellis L., Cascio M., and Di Marzo D. The endocannabiniod system: a general view and latest additions. Br J Pharmacol 141 (2004) 765-774
45. Di Marzo D., and Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 8 (2005) 585-589
46. Howlett A., Breivogel C., Childers S., Deadwyler S., Hampson R., and Porrino L. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47 (2004) 345-358
47. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46 (2006) 101-122
48. Osei-Hyiaman D., Depetrillo M., Harvey-White J., et al. Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81 (2005) 273-282
49. Horvath T. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 112 (2003) 323-326
50. Pagotto U., Vicennati V., and Pasquali R. The endocannabinoid system and the treatment of obesity. Ann Med 37 (2005) 270-275
51. Rinaldi-Carmona M., Barth F., Heaulme M., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350 (1994) 240-244
52. Rinaldi-Carmona M., Barth F., Heaulme M., et al. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56 (1995) 1941-1947
53. European Agency for the Evaluation of Medicinal Products. Rimonabant: summary of product characteristics (2006). http://www.emea.eu.int/humandocs/PDFs/EPAR/acomplia/H-666-PI-en%20.pdf (accessed July 26, 2006)
54. Carai M., Colombo G., and Gessa G. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77 (2005) 2339-2350
55. Thomas Boyd S., and Fremming B. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 39 (2005) 684-690
56. Liu Y., Connoley I., Wilson C., and Stock M. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 29 (2005) 183-187
57. Osei-Hyiaman D., DePetrillo M., Pacher P., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2006) 1298-1305
58. Cota D., Marsicano G., Tschop M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
59. Despres J., Golay A., Sjostrom L., and for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
60. Gomez R., Navarro M., Ferrer B., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22 (2002) 9612-9617
61. Gary-Bobo M., Elachouri G., Scatton B., Le Fur G., Oury-Donat F., and Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69 (2006) 471-478
62. Van Gaal L., Rissanen A., Scheen A., Ziegler O., Rossner S., and for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
63. Pi-Sunyer F., Aronne L., Heshmati H., Devin J., Rosenstock J., and for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295 (2006) 761-775
64. Scheen A., Finer N., Hollander P., Jensen M., Van Gaal L., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 368 (2006) 1160-1172
65. Curioni C., and André C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 4 (2006) CD006162
66. ClinicalTrials.gov. Atherosclerosis underlying development assessed by intima-media thickness in patients on rimonabant (AUDITOR) (December, 2005). http://www.clinicaltrials.gov/ct/show/NCT00228176?order=2 (accessed Feb 11, 2006)
67. ClinicalTrials.gov. CRESCENDO: comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes (December, 2005). http://www.clinicaltrials.gov/ct/show/NCT00263042?order=3 (accessed Feb 11, 2006)
68. ClinicalTrials.gov. STRADIVARIUS (Strategy to reduce atherosclerosis development involving administration of rimonabant-the intravascular ultrasound study) (December, 2005). http://www.clinicaltrials.gov/ct/show/NCT00124332?order=1 (accessed Feb 11, 2006)
69. Wadden T., Berkowitz R., Womble L., Sarwer D., Arnold M., and Steinberg C. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 8 (2000) 431-437
70. Sari R., Balci M., Cakir M., Altunbas H., and Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 30 (2004) 159-167
71. Nissen S., Wolski K., and Topol E. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
72. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
73. Parmentier-Batteur S., Jin K., Mao X., Xie L., and Greenbert D. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22 (2002) 9771-9775
74. Underdown N., Hiley R., and Ford W. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 146 (2005) 809-816
75. Padwal R. Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004. Obes Res 13 (2005) 1905-1908
76. Farrigan C., and Pang K. From the analysts's couch. Obesity market overview. Nat Rev Drug Discov 1 (2002) 257-258
77. Spiegelman B., and Flier J. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543